Amifostine
Based on 17 publication(s) in Google Scholar
Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine protects cells from damage by scavenging oxygen-derived free radicals. Amifostine reduces renal toxicity and has antiangiogenic action.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.95%
- No. CAS: 20537-88-6
- Fòrmula: C5H15N2O3PS
- Peso molecular:214.22
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-B0215
AcetylcysteineMucolytic Agent -
HY-16561
ResveratrolPolyphenolic Phytoalexin -
HY-15484
Pifithrin-α hydrobromidep53 Inhibitor -
HY-137864
Amifostine thiolRadioprotector/p53 Activator -
HY-B0240
DisulfiramALDH1 Inhibitor -
HY-16569
ColchicineTubulin Inhibitor -
HY-17394
CisplatinDNA Alkylator -
HY-15510
Tenovin-6p53 Activator -
HY-108640A
HLI373 dihydrochlorideHdm2 Inhibitor -
HY-Y1891
Tween 80 -
HY-Y0873
PEG300Neutral Polymer -
HY-17561
G-418 disulfateAminoglycoside Antibiotic
Publications Citing Use of MedChemExpress (MCE) Amifostine
More- Mol Cancer. 2024 Oct 19;23(1):234. [Abstract]
- Bioact Mater.2024 May 21:39:191-205. [Abstract]
- Nat Commun. 2025 Dec 8. [Abstract]
- Exp Mol Med. 2026 May;58(5):1642-1656. [Abstract]
- MedComm (2020). 2025 Feb 13;6(2):e70092. [Abstract]
- Cell Commun Signal. 2025 Jan 31;23(1):58. [Abstract]
- Int J Nanomedicine. 2024 Dec 6:19:13135-13148. [Abstract]
- ACS Appl Mater Interfaces. 2023 Mar 29;15(12):15203-15219. [Abstract]
- Int J Radiat Oncol Biol Phys. 2026 Apr 17:S0360-3016(26)00591-2. [Abstract]
- mLife. 2026 Apr 30;5(2):199-216. [Abstract]
- Int J Mol Sci. 2025 May 29;26(11):5238. [Abstract]
- Int Immunopharmacol. 2020 Nov:88:106998. [Abstract]
- Sci Rep. 2023 Jun 28;13(1):10485. [Abstract]
- Cancers (Basel). 2024 Jan 13;16(2):351. [Abstract]
- Histochem Cell Biol. 2026 Jul 28;164(1):67.
- arXiv. 2025 Aug 28.
- University of Pardubice. 2023 Apr 27.
Customer Validation & Images
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
WB
-
RT-PCR
-
Cell Proliferation/Viability Assay
Actividad biológica
Descripciòn
In Vitro
Amifostine (0.78125-100 μM, 24 h) reduces tert-Butyl hydroperoxide (TBHP)-induced cell damage in a dose-dependent manner and significantly reduces H9c2 cells apoptosis at a concentration of 100 μM[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice with myocardial I/R injury[5]
-
Dosage:400 mg/kg
-
Administration:Intravenous injection; 4 hours
-
Result:Attenuated cardiomyocyte apoptosis and reduced the production of I/R-induced ROS.
Significantly reduced the expression of cleaved caspase 3 and Bax while enhanced the expression of SOD1, SOD2 and Bcl2.
Significantly increased SOD activity and reduced MDA levels.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 20537-88-6
-
Appearance Solid
-
Peso molecular 214.22
-
Fòrmula C5H15N2O3PS
-
Color White to off-white
-
SMILES
OP(SCCNCCCN)(O)=O
-
Synonyms
WR2721
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
Anti irradiation nanoparticles shelter immune organ from radio-damage via preventing the IKK/IκB/NF-κB activation. [Abstract]2024 Oct 19;23(1):234. PMID: 39425231 -
Bioact Mater
A DNA tetrahedron-based nanosuit for efficient delivery of amifostine and multi-organ radioprotection. [Abstract]2024 May 21:39:191-205. PMID: 38808157
Amifostine purchased from MedChemExpress. Usage Cited in: Bioact Mater.2024 May 21:39:191-205. [Abstract]
Cell viabilities of A31 cells under different doses of IR (0, 2, 4, 6, 8, and 10 Gy) with pretreatment of tFNAs, Amifostine (AMF, 54 μg/mL; 12 h), or nanosuit (250 nM; 12 h) (n = 5).
-
Nat Commun
2025 Dec 8. PMID: 41361241 -
Exp Mol Med
Cannabidiol triggers fatty acids β-oxidation mediated by Stat2 to facilitate intestinal stem cells regeneration post radiation. [Abstract]2026 May;58(5):1642-1656. PMID: 42120478 -
MedComm (2020)
Cannabidiol restores hematopoietic stem cell stemness in mouse through Atf2-Lrp6 axis after acute irradiation. [Abstract]2025 Feb 13;6(2):e70092. PMID: 39949985
Amifostine purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2025 Feb 13;6(2):e70092. [Abstract]
The dynamics of the numbers of CFUs in the bone marrow from indicated groups within a month post‐irradiation. The results showed that the reduction in colony-forming unit (CFU) counts in mice treated with Amifostine (150 mg/kg; i.p.; single dose) was relatively mild at 7 days post-irradiation.
-
Cell Commun Signal
Ionizing radiation-induced disruption of Rela-Bclaf1-spliceosome regulatory axis in primary spermatocytes causing spermatogenesis dysfunction. [Abstract]2025 Jan 31;23(1):58. PMID: 39891142
Amifostine purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2025 Jan 31;23(1):58. [Abstract]
HE staining of testis among the control group, IR group, Amifostine (50 mg/kg; i.p.) group, NF-κB activator 2 group, and CU-T12-9 group.
Amifostine purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2025 Jan 31;23(1):58. [Abstract]
Protein level alterations of Bclaf1, P-Rela, Rela, Sycp3, and β-actin were analyzed among the control group, IR group, Amifostine (50 mg/kg; i.p.) group, NF-κB activator 2 group, and CU-T12-9 group.
Amifostine purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2025 Jan 31;23(1):58. [Abstract]
RT-qPCR analysis of Spliceosome-related gene expression levels across the control group, IR group, Amifostine (50 mg/kg; i.p.) group, NF-κB activator 2 group, and CU-T12-9 group.
-
Int J Nanomedicine
Self-Assembled EGCG Nanoparticles with Enhanced Intracellular ROS Scavenging for Skin Radioprotection. [Abstract]2024 Dec 6:19:13135-13148. PMID: 39670199 -
ACS Appl Mater Interfaces
Amifostine-Loaded Nanocarrier Traverses the Blood-Brain Barrier and Prevents Radiation-Induced Brain Injury. [Abstract]2023 Mar 29;15(12):15203-15219. PMID: 36917732 -
Int J Radiat Oncol Biol Phys
Unraveling the Redox Mechanisms Underlying FLASH Radiotherapy: Critical Dose Thresholds and NRF2-Driven Sparing of Tissue. [Abstract]2026 Apr 17:S0360-3016(26)00591-2. PMID: 42002152 -
mLife
The synthetic estradiol analog E0703 enhances Akkermansia muciniphila growth for radiation-induced intestinal damage repair. [Abstract]2026 Apr 30;5(2):199-216. PMID: 42079447 -
Int J Mol Sci
New Cellular Interactions Due to the Radioprotective Effect of N-Acetylcysteine in a Model of Radiation-Induced Pancreatitis. [Abstract]2025 May 29;26(11):5238. PMID: 40508047 -
Int Immunopharmacol
Amifostine ameliorates induction of experimental autoimmune encephalomyelitis: Effect on reactive oxygen species/NLRP3 pathway. [Abstract]2020 Nov:88:106998. PMID: 33182064 -
Sci Rep
Amifostine attenuates bleomycin-induced pulmonary fibrosis in mice through inhibition of the PI3K/Akt/mTOR signaling pathway. [Abstract]2023 Jun 28;13(1):10485. PMID: 37380638 -
Cancers (Basel)
Mitochondria-Targeted Nitronyl Nitroxide Radical Nanoparticles for Protection against Radiation-Induced Damage with Antioxidant Effects. [Abstract]2024 Jan 13;16(2):351. PMID: 38254840 -
-
-
Solvente y solubilidad
In Vitro:
H2O : 100 mg/mL (466.81 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (466.81 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Kouvaris, J.R., V.E. Kouloulias, and L.J. Vlahos, Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist, 2007. 12(6): p. 738-47. [Content Brief]
[2]. D Maurici, et al. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene. 2001 Jun 14;20(27):3533-40. [Content Brief]
[3]. Efstathia Giannopoulou, et al. Amifostine inhibits angiogenesis in vivo. J Pharmacol Exp Ther. 2003 Feb;304(2):729-37. [Content Brief]
[4]. Michael I Koukourakis, et al. Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha. Cancer Chemother Pharmacol. 2004 Jan;53(1):8-14. [Content Brief]
[5]. Shao-Ze Wu, et al. Amifostine Pretreatment Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting Apoptosis and Oxidative Stress. Oxid Med Cell Longev. 2017;2017:4130824. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 4.6681 mL | 23.3405 mL | 46.6810 mL | 116.7025 mL |
| 5 mM | 0.9336 mL | 4.6681 mL | 9.3362 mL | 23.3405 mL | |
| 10 mM | 0.4668 mL | 2.3340 mL | 4.6681 mL | 11.6702 mL | |
| 15 mM | 0.3112 mL | 1.5560 mL | 3.1121 mL | 7.7802 mL | |
| 20 mM | 0.2334 mL | 1.1670 mL | 2.3340 mL | 5.8351 mL | |
| 25 mM | 0.1867 mL | 0.9336 mL | 1.8672 mL | 4.6681 mL | |
| 30 mM | 0.1556 mL | 0.7780 mL | 1.5560 mL | 3.8901 mL | |
| 40 mM | 0.1167 mL | 0.5835 mL | 1.1670 mL | 2.9176 mL | |
| 50 mM | 0.0934 mL | 0.4668 mL | 0.9336 mL | 2.3340 mL | |
| 60 mM | 0.0778 mL | 0.3890 mL | 0.7780 mL | 1.9450 mL | |
| 80 mM | 0.0584 mL | 0.2918 mL | 0.5835 mL | 1.4588 mL | |
| 100 mM | 0.0467 mL | 0.2334 mL | 0.4668 mL | 1.1670 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Amifostine Related Classifications
HY-B0639 Related Classifications
Powered by Bioz